Jenner Institute

R21 anti-malaria vaccine is a game changer: scientist who helped design it reflects on 30 years of research, and what it promises

Retrieved on: 
Thursday, April 25, 2024

Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.What makes malaria such a difficult disease to beat?Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.

Key Points: 


Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.

What makes malaria such a difficult disease to beat?

  • Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.
  • Additionally, the malaria parasite goes through four life cycle stages.
  • Medical researchers have been trying to make malaria vaccines for over 100 years.

How does the R21/Matrix-M vaccine work?

  • An antigen is any substance that causes the body to make an immune response against that substance.
  • We targeted the sporozoites, which is the form that the mosquito inoculates into your skin.
  • Read more:
    Two new malaria vaccines are being rolled out across Africa: how they work and what they promise

A child dies every minute from malaria in Africa. Why are children more susceptible than adults?

  • The age you’re most likely to die of malaria in Africa is when you are one year old.
  • For the first six months you are protected largely by your mother’s immunity and the antibodies she transfers during pregnancy.
  • Without malaria, children would be healthier in general — the disease makes you susceptible to other infections.

What about the pace of vaccine rollouts?

  • We’ve been disappointed that it’s taken more than six months to roll out the R21 vaccine since it was approved in October last year.
  • Compare that to a COVID-19 vaccine from Oxford and AstraZeneca that was approved on New Year’s Eve 2020 and rolled out in several countries the very next week.

How big a role will vaccines have in the fight to eradicate malaria?

  • Nobody is quite sure how many of the older tools such as insecticides and bed nets we need to carry on with.
  • Anti-malaria medication only lasts for days and parasites are building up resistance against these drugs as well.
  • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.
  • The Serum Institute of India, our manufacturing and commercial partner, can produce hundreds of millions of doses each year.


Adrian Hill receives funding from government and charitable funders of malaria vaccine development. He has received funding awarded to the University of Oxford from the Serum Institute of India to support clinical trials of the R21/Matrix-M vaccine. He may benefit for a share of any royalty stream to Oxford University from the vaccine.

Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster

Retrieved on: 
Monday, February 26, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240219023333/en/
    From left to right: Baseimmune co-founders Ariane C. Gomes (Chief Scientific Officer), Phillip Kemlo (Chief Technology Officer), and Joshua Blight (Chief Executive Officer).
  • Photo credit: Baseimmune
    “We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital.
  • This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens,” said Joshua Blight, CEO & Co-Founder, Baseimmune.
  • By using big data and a design algorithm, Baseimmune has been able to shorten the time it takes to develop a vaccine candidate.

'We could eradicate malaria by 2040' says expert after revolutionary vaccine is approved by WHO

Retrieved on: 
Tuesday, October 3, 2023

Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.

Key Points: 
  • Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.
  • The Conversation Weekly spoke to chief investigator Adrian Hill, who is also director of the Jenner Institute at the University of Oxford, about this revolutionary vaccine.

Why is the R21/Matrix vaccine a game-changer?

    • The best vaccine prior to this was about 50% over a year, and lower than that over three years.
    • The big difference is how you can manufacture it at a scale that is really needed to protect most of the children who need a malaria vaccine in Africa.
    • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.

Why has developing a malaria vaccine been so difficult?

    • Malaria is not a virus, it’s not a bacterium.
    • This is one of the reasons that malaria is super complex.
    • If you can get a really good vaccine for one of those, you will break the cycle of transmission.
    • It’s a silent infection until it gets into the blood and starts multiplying inside your red blood cells.
    • So the sporozoite is a natural target to try and kill the parasite before it multiplies very quickly.

Tell us about past attempts to develop a malaria vaccine

    • In about 1943, there was a trial of the whole malaria parasite vaccine candidate in New York with zero efficacy.
    • And then within 10 years we had 5,000 candidates because everyone hoped that the gene they had sequenced might be a malaria vaccine.

Why aren’t vaccines for whole parasites effective against malaria?

    • It’s the same reason that just getting infected once by malaria doesn’t give you protection against the next infection.
    • In the areas of malaria where we test our vaccines in Africa, some children get up to eight episodes in three or four months.
    • They get quite unwell with the first and three weeks later they’re having a second bout and so on.

Will we ever eradicate malaria entirely?

    • Malaria is very high on the list of diseases we want to eradicate.
    • I don’t think it’s going to happen in five years or 10 years, but it should happen in something like 15 years.

The long road to a new malaria vaccine, told by the scientists behind the breakthrough – podcast

Retrieved on: 
Tuesday, October 3, 2023

In this episode of The Conversation Weekly podcast, we find out why it’s been so hard to find a malaria vaccine – and hear from the scientists behind the new breakthrough.

Key Points: 
  • In this episode of The Conversation Weekly podcast, we find out why it’s been so hard to find a malaria vaccine – and hear from the scientists behind the new breakthrough.
  • In 2021, 619,000 people died from malaria, the majority of them children.
  • The search for a vaccine has been underway for decades, but it’s particularly difficult due to the complexity of the malaria parasite.
  • “It begins with a mosquito bite,” says Faith Osier, co-director of the Institute of Infection at Imperial College London.

Oxford University breakthrough on global COVID-19 vaccine

Retrieved on: 
Monday, November 23, 2020

Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said:

Key Points: 
  • Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said:
    "These findings show that we have an effective vaccine that will save many lives.
  • Vaccitech is proud to have been a small part of the team, together with Oxford University and AstraZeneca, that moved this vaccine from concept to reality in record time.
  • Professor Louise Richardson, Vice-Chancellor at the University of Oxford, said:
    "This is a great day for the University of Oxford and for universities everywhere.
  • TheVaccitechprime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford.

Vaccitech receives government grant for COVID-19 vaccine research

Retrieved on: 
Thursday, August 27, 2020

The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.

Key Points: 
  • The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.
  • With the grant proceeds, Vaccitech will complete preclinical studies and manufacture sufficient quantities required to initiate a Phase 1 clinical study of its new COVID-19 vaccine candidate in 2021.
  • The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford.
  • Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.

Vaccitech receives government grant for COVID-19 vaccine research

Retrieved on: 
Thursday, August 27, 2020

The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.

Key Points: 
  • The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.
  • With the grant proceeds, Vaccitech will complete preclinical studies and manufacture sufficient quantities required to initiate a Phase 1 clinical study of its new COVID-19 vaccine candidate in 2021.
  • The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford.
  • Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.

Vaccitech receives government grant for COVID-19 vaccine research

Retrieved on: 
Thursday, August 27, 2020

The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.

Key Points: 
  • The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.
  • With the grant proceeds, Vaccitech will complete preclinical studies and manufacture sufficient quantities required to initiate a Phase 1 clinical study of its new COVID-19 vaccine candidate in 2021.
  • The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford.
  • Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.

Vaccitech receives government grant for COVID-19 vaccine research

Retrieved on: 
Thursday, August 27, 2020

The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.

Key Points: 
  • The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech's research efforts.
  • With the grant proceeds, Vaccitech will complete preclinical studies and manufacture sufficient quantities required to initiate a Phase 1 clinical study of its new COVID-19 vaccine candidate in 2021.
  • The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford.
  • Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.